Fingolimod in new therapeutic indication: Added benefit not proven
The immunosuppressive drug fingolimod (trade name: Gilenya) was approved for an expanded therapeutic indication in May 2014: It is now also available for adults with highly active relapsing remitting multiple sclerosis (RRMS) ...
Oct 10, 2014
0
0